Results 91 to 100 of about 20,657 (229)
Advanced Science, EarlyView.A GSH‐responsive MOF nanoplatform acts as a Photothermolysis‐Targeting Conjugate (PTTAC). Through sophisticated step‐wise nuclear delivery, it enables NIR‐II light‐triggered photothermal degradation of BRD4. This precise strategy induces robust immunogenic cell death (ICD) and powerfully synergizes with anti‐PD‐L1 blockade to elicit a potent systemic ...
Luyi Wang +10 more
wiley +1 more source
On the metric dimension of Cartesian powers of a graph
, 2019 A set of vertices $S$ resolves a graph if every vertex is uniquely determined by its vector of distances to the vertices in $S$. The metric dimension of a graph is the minimum cardinality of a resolving set of the graph.
Jiang, Zilin, Polyanskii, Nikita
core +1 more source
Cancers, 2021 Simple Summary The BET bromodomain inhibitor JQ1 slows tumor growth in preclinical models of pancreatic cancer. However, as a single agent, it does not induce tumor regressions. We hypothesized that JQ1 would sensitize pancreatic tumors to gemcitabine, a
A. Miller +9 more
semanticscholar +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Cell Death and Disease, 2021 Chondrosarcoma (CHS) is the second most common bone malignancy with limited therapeutic approaches. Our previous study has found that Yes associated protein 1 (YAP1) is downregulated in CHS cells treated with bromodomain and extraterminal domain (BET ...
Huan-Tian Zhang +15 more
semanticscholar +1 more source
The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
Melanoma Research, 2018 Inhibition of BRAF improves therapeutic efficacy of BRAF-mutant melanoma. However, drug resistance to BRAF inhibitor is inevitable, and the drug resistance mechanisms still remain to be elucidated. Here, BRAFV600E mutant cells A375 and SK-MEL-28 were chosen and treated with BRAF inhibitor vemurafenib, and the results showed that the ERK signaling ...
Zhao, Bei, Cheng, Xiankui, Zhou, Xiyuan
openaire +3 more sources
BRD9 inhibition as potential treatment option for testicular germ cell tumors
Andrology, EarlyView.Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen +5 more
wiley +1 more source
Loci specific epigenetic drug sensitivity. [PDF]
, 2020 Therapeutic targeting of epigenetic modulators offers a novel approach to the treatment of multiple diseases. The cellular consequences of chemical compounds that target epigenetic regulators (epi-drugs) are complex.
Pilko, Anna +2 more
core +1 more source
Journal of Molecular and Cellular Cardiology, 2020 BRD4 is a member of the BET family of epigenetic regulators. Inhibition of BRD4 by the selective bromodomain inhibitor JQ1, alleviates thoracic aortic constriction-induced cardiac hypertrophy and heart failure. However, whether BRD4 inhibition by JQ1 has
Jing Mu +4 more
semanticscholar +1 more source
Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells
PLoS ONE, 2014 High level MYC expression is associated with almost all human cancers. JQ1, a chemical compound that inhibits MYC expression is therapeutically effective in preclinical animal models in midline carcinoma, and Burkitt's lymphoma (BL). Here we show that JQ1 does not inhibit MYC expression to a similar extent in all tumor cells. The BL cells showed a ∼90%
Fowler, Trent +8 more
openaire +5 more sources